U.S. Markets closed

Becton, Dickinson and Company (BDX)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
203.33+1.31 (+0.65%)
At close: 4:01PM EDT

203.33 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch
BCRBAXAPDADPCB

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417
United States
201-847-6800
http://www.bd.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees50,928

Key Executives

NameTitlePayExercisedAge
Mr. Vincent A. ForlenzaChairman and Chief Exec. Officer3.15M9.03M64
Mr. Thomas E. Polen Jr.Pres1.44M1.19M44
Mr. Christopher R. ReidyChief Financial Officer, Chief Admin. Officer and Exec. VP1.68MN/A60
Mr. Alexandre ConroyExec. VP and Pres of Europe, EMA & the Americas1.24M1.86M54
Dr. Ellen R. Strahlman M.D., M.H.Sc.Chief Medical Officer and Exec. VP of R&D1.33MN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women’s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation, and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. It has a strategic collaboration with FlowJo, LLC. Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.